Nanoparticles capable of targeting glioma cells and preparation method and application thereof

By mixing PLGA nanoparticles with glioma cell membranes, nanoparticles with homologous targeting and homing effects were prepared, which solved the problems of blood-brain barrier penetration and biocompatibility, significantly inhibited the formation of glioma migration. Improve the therapeutic effect of glioma cells.

CN118267359BActive Publication Date: 2024-12-06THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410233453.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-01
Publication Date
2024-12-06
Estimated Expiration
2044-03-01

AI Technical Summary

Technical Problem

The prior art is difficult to effectively pass through the blood-brain barrier and act directly on glioma cells, and drug treatment of glioma cells has safety and biocompatibility challenges.

Method used

The nanoparticles with spherical polylactic acid-glycolic acid copolymer (PLGA) are mixed with extracted glioma cell membranes that can express RGD sequences to prepare nanoparticles with homologous targeting and homing effects, and act on the blood-brain barrier. Glioma cells.

Benefits of technology

The good blood-brain barrier permeability and biocompatibility of nanoparticles were achieved, which significantly inhibited the formation of glioma migratory bodies and cell migration, and had efficient targeting and safety, enhancing the therapeutic potential of glioma cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118267359B_ABST
    Figure CN118267359B_ABST
Patent Text Reader

Abstract

The present invention discloses a nanoparticle capable of targeting glioma cells and a preparation method and application thereof. The preparation method thereof comprises the following steps: step S1: preparing nanoparticles of spherical polylactic-co-glycolic acid copolymer; step S2: extracting the cell membrane of glioma cells capable of expressing RGD sequence; step S3: mixing the nanoparticles of polylactic-co-glycolic acid copolymer prepared in step S1 with the cell membrane of glioma cells capable of expressing RGD sequence extracted in step S2, and obtaining nanoparticles capable of targeting glioma cells. The nanoparticles can be used as a drug for preparing and treating glioma. The nanoparticles provided by the present invention can significantly inhibit the formation of glioma migratory bodies and cell migration, and have a positive therapeutic effect on the treatment of glioma cells. Due to its high efficiency targeting, good blood-brain barrier permeability, good stability and biosafety, it has great potential as a targeted drug carrier.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of targeted drugs, and in particular to a nanoparticle capable of targeting glioma cells, and a preparation method and application thereof. Background Art

[0002] Glioma cells are common glial cells in the brain. Due to certain reasons, the cells undergo gene mutations, causing abnormal proliferation of glial cells, forming glioma cells, including astrocytes, oligodendrocytes and ependymal cells. Glial cells are normal cells in the body, but due to factors such as trauma or ionizing radiation and changes in the internal environment of the body, normal glial cells can undergo abnormal proliferation, resulting in various types of glioma cells, which are pathologically classified as intracranial malignant tumors.

[0003] At present, the mainstream treatment for glioma cells is through surgery, supplemented by radiotherapy, chemotherapy and gene therapy. Because glioma cells exist in the human brain, surgery is difficult and difficult to remove. Once glioma cells form migratory bodies or cell migration occurs, it will cause serious harm to patients, and in severe cases, it will endanger the patient's life. Therefore, glioma cells need to be treated with drug-assisted therapy. Due to the existence of the blood-brain barrier, it is difficult for drugs targeting glioma cells to act directly on glioma cells. And because glioma cells are located in the human brain, there are higher requirements for the safety and biocompatibility of the drugs they act on, which greatly limits the drug treatment of glioma cells. Summary of the invention

[0004] In view of the deficiencies of the prior art, the object of the present invention is to provide a nanoparticle that has good blood-brain barrier permeability, good biocompatibility and high safety and can target glioma cells.

[0005] Another object of the present invention is to provide a specific method for preparing the above-mentioned nanoparticles capable of targeting glioma cells.

[0006] Another object of the present invention is to provide a specific application of the above-mentioned nanoparticles capable of targeting glioma cells.

[0007] In order to achieve the above object, the present invention is implemented by the following technical scheme: a method for preparing nanoparticles capable of targeting glioma cells, comprising the following steps:

[0008] Step S1: preparing spherical poly(lactic acid-co-glycolic acid) nanoparticles;

[0009] Step S2: extracting the cell membrane of glioma cells capable of expressing the RGD sequence;

[0010] Step S3: The nanoparticles of polylactic acid-glycolic acid copolymer prepared in step S1 are mixed with the cell membranes of glioma cells capable of expressing the RGD sequence extracted in step S2 to prepare nanoparticles capable of targeting glioma cells.

[0011] The working principle of this technical solution is that polylactic acid-glycolic acid copolymer (PLGA) is a degradable functional polymer with good biosafety. It has been approved by the FDA and the European Medicines Agency as a pharmaceutical excipient for surgical sutures, tissue engineering, and injectable microspheres, implants, gels and other preparations; PLGA, as a biodegradable material with a high degree of application, is one of the most widely used excipients in clinical injectable sustained-release injections. The present invention uses PLGA as a base material, and its safety and biocompatibility are well guaranteed. It is mixed with the cell membrane of glioma cells that can express the RGD sequence to prepare nanoparticles. The nanoparticles are covered with glioma cell membranes and have good homologous targeting and homing effects. They can smoothly pass through the blood-brain barrier and act on glioma cells, making them have medicinal potential as drug carriers. In addition, the nanoparticles can significantly inhibit the formation of glioma migratory bodies and cell migration, which is an additional discovery of the nanoparticles, and have a positive therapeutic effect on the treatment of glioma cells.

[0012] In order to better implement the method of the present invention, further, in the step S1, a solvent volatilization method is used to prepare spherical polylactic acid-glycolic acid copolymer nanoparticles.

[0013] In order to better implement the method of the present invention, further, the specific process of preparing spherical polylactic acid-glycolic acid copolymer nanoparticles by solvent evaporation method is as follows:

[0014] Step S11: first, 50 mg of poly(lactic acid-co-glycolic acid) was added to 5 mL of acetone and dissolved by ultrasonication to prepare a mixture;

[0015] Step S12: using a disposable syringe, uniformly drip the mixture obtained in step S11 into 40 ml of polyvinyl alcohol aqueous solution, stirring at room temperature for 4 hours, and obtaining spherical polylactic acid-glycolic acid copolymer nanoparticles after the organic solvent is completely evaporated.

[0016] In order to better implement the method of the present invention, further, the disposable syringe used in step S12 has a syringe barrel capacity of 20 ml and a needle of 5 ml.

[0017] In order to better implement the method of the present invention, further, the mass percentage of polyvinyl alcohol in the polyvinyl alcohol aqueous solution in step S12 is 0.5%.

[0018] In order to better implement the method of the present invention, further, in step S2, the specific process of extracting the cell membrane of glioma cells capable of expressing the RGD sequence is:

[0019] Step S21: preparing gcGFP-RGD-tag-Lamp2 adenovirus;

[0020] Step S22: adding the prepared gcGFP-RGD-tag-Lamp2 adenovirus into glioma cells for culturing;

[0021] Step S23: After culturing for a period of time, puromycin is added to screen the glioma cell lines that are successfully transfected with adenovirus and the glioma cell lines that can stably express RGD;

[0022] Step S24: The cell membrane of the cell line of successfully transfected glioma cells was extracted using a cell membrane extraction kit, and the protein concentration was measured using a BCA kit.

[0023] In order to better implement the method of the present invention, further, in the step S21, the gcGFP-RGD-tag-Lamp2 adenovirus prepared has a Sense primer sequence of: -TGTCGTGGTGATAAAGGTCCAGATTGT-, and an Antisense primer sequence of: -ACAGCACCACTATTTCCAGGTCTAACA-.

[0024] In order to better implement the method of the present invention, further, the specific process of step S3 is:

[0025] Step S31: mixing the cell membrane of the glioma cell capable of expressing the RGD sequence and the nanoparticles of poly(lactic-co-glycolic acid) copolymer at a mass ratio of 1:1, and ultrasonicating for 3-5 minutes to obtain a mixture;

[0026] Step S32: The mixture obtained in step S31 is then extruded through a 0.22 μm porous polycarbonate membrane 8-10 times using an Avestin micro-extruder to collect the obtained nanoparticles capable of targeting glioma cells.

[0027] A nanoparticle capable of targeting glioma cells, wherein the spherical nanoparticle is prepared by the above-mentioned preparation method, the dynamic light scattering particle size of the nanoparticle is 180-220nm, and the Zeta potential of the nanoparticle is about -10--15.

[0028] A drug for treating glioma, which is prepared with the above-mentioned nanoparticles capable of targeting glioma cells as the main component and the rest as auxiliary components of pharmaceutically acceptable, non-toxic and non-inert pharmaceutical carriers and / or excipients to humans and animals, and can effectively inhibit the formation of glioma migratory bodies and the migration of glioma cells.

[0029] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0030] (1) The nanoparticles provided by the present invention contain the cell membrane of glioma cells. Due to their homology, they are guaranteed to have efficient targeting to glioma cells, and they have good blood-brain barrier permeability and can smoothly pass through the blood-brain barrier to act on glioma cells;

[0031] (2) After the nanoparticles provided by the present invention are co-cultured with glioma cells, they can significantly inhibit the formation of glioma migratory bodies and cell migration, and have a positive therapeutic effect on the treatment of glioma cells;

[0032] (3) The nanoparticles provided by the present invention have good biocompatibility and safety, will not cause additional damage to the organs of the organism, and meet the medicinal standards of the organism;

[0033] (4) The nanoparticles provided by the present invention have great potential as targeted drug carriers due to their high targeting efficiency, good blood-brain barrier permeability, good stability and biosafety. Their medicinal value deserves further exploration and research. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments with reference to the following drawings:

[0035] Figure 1 TEM image of the nanoparticles prepared by the present invention;

[0036] Figure 2 is the TEM image of PLGA sphere;

[0037] Figure 3 This is a comparison diagram of the particle sizes of the nanoparticles prepared in the present invention and PLGA spheres measured by DLS;

[0038] Figure 4 Zeta potential diagram of the nanoparticles and PLGA spheres prepared in the present invention;

[0039] Figure 5 This is a HE staining image of the mouse heart three days after the nanoparticles and PLGA spheres prepared in the present invention were injected into the mouse;

[0040] Figure 6This is a HE staining image of the mouse liver three days after the nanoparticles and PLGA spheres prepared in the present invention were injected into the mouse;

[0041] Figure 7 This is a HE staining image of the spleen of mice three days after the nanoparticles and PLGA balls prepared in the present invention were injected into mice;

[0042] Figure 8 This is a HE staining image of the mouse lungs three days after the nanoparticles and PLGA spheres prepared in the present invention were injected into the mice;

[0043] Fig. 9 This is a HE staining image of the mouse kidney three days after the nanoparticles and PLGA spheres prepared in the present invention were injected into the mouse;

[0044] Fig.10 This is a live imaging diagram of the aggregation of the nanoparticles and PLGA spheres prepared by the present invention in the brain of mice one hour after being injected;

[0045] Fig.11 This is a live imaging diagram of the aggregation of the nanoparticles and PLGA spheres prepared by the present invention in the brain of mice two hours after injection;

[0046] Fig.12 This is the fluorescence image of RGD-CM / PLGA engulfed by U87 cells detected by laser confocal microscopy at 2 hours;

[0047] Fig.13 Laser confocal microscopy images of migratory bodies in the glioma group and RGD-CM / PLGA glioma group;

[0048] Fig.14 Laser confocal microscopy images of glioma group and RGD-CM / PLGA cell migration. DETAILED DESCRIPTION

[0049] In order to make the purpose, process conditions and advantages of the present invention more clearly understood, the present invention is further described in detail in conjunction with the following embodiments, but the embodiments of the present invention are not limited thereto. Without departing from the above-mentioned technical ideas of the present invention, various substitutions and changes are made according to the common technical knowledge and customary means in the field, which should all be included in the scope of the present invention. The specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0050] Embodiment 1:

[0051] This embodiment provides a nanoparticle that can target glioma cells. The projection electron microscope shows that the nanoparticle has a spherical shape, such as Figure 1 As shown, compared with spherical poly(lactic-co-glycolic acid) (PLGA) nanoparticles, Figure 2As shown, the nanoparticles capable of targeting glioma cells have an additional membrane structure on their surface.

[0052] The specific preparation method is as follows:

[0053] (1) Preparation of spherical poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles by solvent evaporation method: First, 50 mg of PLGA was added to 5 mL of acetone and dissolved by ultrasonication. The mixture was uniformly dripped into 40 mL of poly(vinyl alcohol) (PVA) aqueous solution using a disposable syringe and stirred at room temperature for 4 hours to evaporate the organic solvent.

[0054] The capacity of the syringe barrel of the disposable syringe is 20 ml, the needle is 5 ml, and the mass percentage of polyvinyl alcohol in the polyvinyl alcohol aqueous solution is 0.5%;

[0055] (2) Establishment of RGD-transfected glioma cell lines and extraction of cell membranes: Design and purchase of gcGFP-RGD-tag-Lamp2 adenovirus; use adenovirus to transfect glioma cells, add puromycin to screen for glioma cells that stably express RGD (i.e., cell lines of successfully transfected glioma cells); use a cell membrane extraction kit to extract the cell membranes of glioma cell lines that stably express RGD, and use a BCA kit to measure the protein concentration;

[0056] Among them, the Sense primer sequence of the prepared gcGFP-RGD-tag-Lamp2 adenovirus is: -TGTCGTGGTGATAAAGGTCCAGATTGT-, and the Antisense primer sequence is: -ACAGCACCACTATTTCCAGGTCTAACA-;

[0057] (3) Nanoparticles that can target glioma cells (i.e., RGD-CM / PLGA nanoparticles) were prepared by ultrasound and extrusion: the cell membrane of glioma cells that can express the RGD sequence and nanoparticles of polylactic acid-glycolic acid copolymer were mixed in a mass ratio of 1:1 and ultrasonicated for 3-5 minutes to obtain a mixture; the mixture was then extruded through a 0.22 μm porous polycarbonate membrane 8-10 times using an Avestin microextruder to collect the RGD-CM-PLGA nanoparticle mixture.

[0058] The particle size of the prepared nanoparticles (i.e., RGD-CM / PLGA nanoparticles) was measured by DLS, and the dynamic light scattering particle size was about 205 nm, and the Zeta potential was about -13, as shown in FIG. Figure 3 , Figure 4 shown.

[0059] Embodiment 2:

[0060] In this example, the prepared nanoparticles were subjected to a biosafety experiment, and the specific experimental process is as follows:

[0061] The prepared nanoparticles were injected into several mice. After culturing the mice for three days, the mice were randomly killed and their blood, heart, liver, spleen, lung and kidney were taken. Blood was collected using anticoagulant blood vessels for routine blood tests and biochemical monitoring. Each organ tissue was fixed with 4% paraformaldehyde, embedded in paraffin and sectioned, and stained with hematoxylin-eosin.

[0062] PLGA balls were used as blank control group.

[0063] The results are as follows Figures 5 to 9 As shown, no damage or pathological changes were found in the blood, heart, liver, spleen, lung and kidney of the mice. It can be seen that the nanoparticles prepared by the present invention have good biosafety.

[0064] Embodiment 3:

[0065] In this example, the prepared nanoparticles were subjected to a blood-brain barrier permeability test, and the specific experimental process is as follows:

[0066] Since RGD peptide is highly expressed on the tumor cell membrane and has good brain targeting and vascular endothelial targeting, nanoparticles were injected through the tail vein and their brain accumulation was detected within 1 or 2 hours by in vivo imaging of small animals.

[0067] PLGA balls were used as blank control group.

[0068] The experimental results are shown in 10. Fig.11 As shown, the higher the fluorescence intensity, the more aggregation there is, which proves that the nanoparticles prepared in the present invention have good blood-brain barrier permeability.

[0069] Embodiment 4:

[0070] In this example, the prepared nanoparticles were subjected to a targeting experiment, and the specific experimental process is as follows:

[0071] The nanoparticles prepared by the present invention were co-incubated with glioma cells, the nanoparticles (RGD-CM / PLGA nanoparticles) were labeled with Dio dye, and the tumor cells (U87) were labeled with DAPI dye. Laser confocal microscopy imaging showed that RGD-CM / PLGA and tumor cells were highly co-localized.

[0072] After 2 hours, laser confocal microscopy imaging showed that Fig.12As shown, the RGD-CM / PLGA nanoparticles are basically completely engulfed by tumor cells (U87). It can be seen that the nanoparticles prepared by the present invention cover the surface of the PLGA sphere with glioma cell membranes, so that it has good homologous targeting and homing effects, that is, the RGD-CM / PLGA nanoparticles have high efficiency in targeting glioma cells.

[0073] Embodiment 5:

[0074] This example experiments the effect of the prepared nanoparticles on glioma cells, and the experimental process is as follows:

[0075] The nanoparticles prepared by the present invention were added to the cultured glioma cells for co-culture. The cells were observed under a microscope to be in the logarithmic growth phase and then plated. The nanoparticles were mixed with 5×10 4 After mixing, the GBM cells were evenly spread on the glass bottom of the confocal culture dish and returned to the incubator for culture for 14-16 hours. After the culture, they were fixed with 2.5% paraformaldehyde for 15 minutes and stained with wheat germ agglutinin (WGA) for 15 minutes. The difference in the number of migratory bodies formed was observed using a laser confocal microscope, and the data were quantified by the ratio of the number of migratory bodies to the number of cell bodies.

[0076] according to Fig.13 , Fig.14 It can be seen that after the nanoparticles prepared by the present invention are co-cultured with glioma cells, the formation of glioma cell migratory bodies can be effectively reduced, and the migration of glioma cells can be effectively reduced.

[0077] Although the embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the claims and their equivalents.

Claims

1. A nanoparticle capable of targeting glioma cells, characterized in that: The dynamic light scattering particle size of the nanoparticles is 180-220 nm, the Zeta potential of the nanoparticles is -10--15, the nanoparticles can be used as the main component, and the rest are pharmaceutically acceptable, non-toxic and non-inert pharmaceutical carriers and / or excipients to prepare a drug for treating glioma. The preparation method of the nanoparticles comprises the following steps: Step S1: preparing spherical polylactic acid-co-glycolic acid nanoparticles by solvent evaporation method; the specific process is as follows: Step S11: first, 50 mg of poly(lactic acid-co-glycolic acid) was added to 5 mL of acetone and dissolved by ultrasonication to prepare a mixture; Step S12: using a disposable syringe, uniformly dripping the mixture obtained in step S11 into 40 ml of polyvinyl alcohol aqueous solution, stirring at room temperature for 4 hours, and obtaining spherical polylactic acid-glycolic acid copolymer nanoparticles after the organic solvent is completely evaporated; Step S2: extracting the cell membrane of glioma cells that can express the RGD sequence, the specific process is as follows: Step S21: prepare gcGFP-RGD-tag-Lamp2 adenovirus; the Sense primer sequence is: -TGTCGTGGTGATAAAGGTCCAGATTGT-, and the Antisense primer sequence is: -ACAGCACCACTATTTCCAGGTCTAACA-; Step S22: adding the prepared gcGFP-RGD-tag-Lamp2 adenovirus into glioma cells for culturing; Step S23: After culturing for a period of time, puromycin is added to screen the glioma cell lines that are successfully transfected with adenovirus and the glioma cell lines that can stably express RGD; Step S24: extracting the cell membrane of the cell line of successfully transfected glioma cells using a cell membrane extraction kit, and measuring the protein concentration using a BCA kit; Step S3: The nanoparticles of polylactic acid-glycolic acid copolymer prepared in step S1 are mixed with the cell membranes of glioma cells capable of expressing the RGD sequence extracted in step S2 to prepare nanoparticles capable of targeting glioma cells.

2. The nanoparticle capable of targeting glioma cells according to claim 1, characterized in that: The disposable syringe used in step S12 has a syringe barrel capacity of 20 ml and a needle of 5 ml.

3. The nanoparticle capable of targeting glioma cells according to claim 1 or 2, characterized in that: The polyvinyl alcohol aqueous solution in step S12 has a mass percentage of polyvinyl alcohol of 0.5%.

4. The nanoparticle capable of targeting glioma cells according to claim 1, characterized in that: The specific process of step S3 is: Step S31: mixing the cell membrane of the glioma cell capable of expressing the RGD sequence and the nanoparticles of poly(lactic-co-glycolic acid) copolymer at a mass ratio of 1:1, and ultrasonicating for 3-5 minutes to obtain a mixture; Step S32: The mixture obtained in step S31 is then extruded through a 0.22 μm porous polycarbonate membrane 8-10 times using an Avestin micro-extruder to collect the obtained nanoparticles capable of targeting glioma cells.